These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 17296819

  • 1. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
    Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR.
    Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
    [Abstract] [Full Text] [Related]

  • 2. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 3. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G.
    Anticancer Res; 2005 May; 25(1B):669-74. PubMed ID: 15816644
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 6. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA, Vogel CL, Gralow JR, Williams D, Procrit Study Group.
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [Abstract] [Full Text] [Related]

  • 7. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE.
    Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
    [Abstract] [Full Text] [Related]

  • 8. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, Maisano R.
    Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.
    Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM, Novotny PJ, Loprinzi CL.
    J Clin Oncol; 2011 Jan 01; 29(1):97-105. PubMed ID: 21098317
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct 01; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P, OBI/EPO-ITA-01/1 study group.
    Support Care Cancer; 2007 Sep 01; 15(9):1057-66. PubMed ID: 17431689
    [Abstract] [Full Text] [Related]

  • 16. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
    Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F, Canadian Eprex Oncology Study Group.
    J Clin Oncol; 2001 Nov 01; 19(21):4126-34. PubMed ID: 11689580
    [Abstract] [Full Text] [Related]

  • 17. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 01; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 18. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group.
    J Clin Oncol; 2001 Jun 01; 19(11):2865-74. PubMed ID: 11387359
    [Abstract] [Full Text] [Related]

  • 19. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N, Fouda M.
    Hematology; 2007 Dec 01; 12(6):533-41. PubMed ID: 17852440
    [Abstract] [Full Text] [Related]

  • 20. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 01; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.